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Abstract
Academic institutions are a well-established source of pharmaceutical innovation. However,
the researchers behind these discoveries are rarely responsible for successful translation of
their findings to the market. It is hypothesized that by enhancing their understanding and
knowledge of the regulatory requirements associated with drug development, the speed of
innovation to market would be increased, while simultaneously decreasing technology
transfer issues that arise as commercially focused projects move from academia to industry.
The usefulness of an associated regulatory readiness tool to guide researchers involved in
commercially focused projects will also be investigated.
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1. Introduction
The laboratory benches of academic institutions are a well-established source of
pharmaceutical innovation, with many of the advancements made in modern medicine
attributable to the basic scientific research carried out in these settings (Silber, 2010; Stevens
et al., 2011). The potential patient impact and wider societal benefits of the discoveries made
in academic settings cannot be overstated. However, while central to the discovery and
development of innovative therapeutic agents, academics and researchers are often not
involved in the later stages of the drug development pathway, that ultimately sees their
discovery brought to the market (Silber, 2010; Starokozhko et al., 2020). Their expertise and
interest is considered to lie in the scientific realm of the drug development pathway, as
distinct from later stages associated with the commercialisation of the associated drug
product (Collins et al., 2016; Greene et al., 2019).
Translating academic discoveries into safe and effective medicinal products is a long and
arduous journey spanning, on average, twelve years and incurring significant financial costs,
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estimated to be in excess of $1 billion (Hudson et al., 2013; Van Norman, 2016). There are no
guarantees that, even after significant investment of time, money, and effort, that products
will successfully emerge from the drug development pipeline (Greene et al., 2019; Seyhan,
2019). Given the complexity of commercialising scientific research, it is little wonder that
researchers and academics often take a narrowly-focused approach to their research,
concentrating their efforts on solving the immediate scientific challenges of their discoveries
rather than looking at a longer term approach to translating this research into a therapeutic
for patients (Executive Office of the President of the United States, 2012; Collins et al., 2016;
Greene et al., 2019).

The path from the lab to the receipt of a marketing authorisation is a challenging one which
encompasses the “Valley of Death” representing the chasm between basic scientific research
and successful commercialisation of a product (Seyhan, 2019). One result of this valley is that
the academic discoveries are not having the anticipated impact on the market and in clinical
settings. Despite the high number of novel therapeutic innovations emerging from academic
institutions, there has not been a corresponding increase in the number of new, effective
therapeutic agents available to treat patients (Freeman et al., 2011; van Dongen et al., 2013;
Palmer et al., 2017; Seyhan, 2019). There are countless reasons why academic discoveries
can fall victim to this valley including cost constraints, lack of infrastructure in universities to
support academics with commercialisation, and navigating the complexities of the regulatory
requirements associated with commercialisation of scientific research (Hait, 2005; HomerVanniasinkam et al., 2012; van Dongen et al., 2013; Sanami et al., 2017; Scannell et al., 2019).

The complex regulatory environment is frequently cited in the literature as one barrier to
translation of scientific research, with Hait (2005) postulating that this environment is
“intimidating to even the most seasoned translational investigator” (Nagpal et al., 2017;
Sanami et al., 2017; Scannell et al., 2019; Starokozhko et al., 2020). Scannell et al., (2019)
identify that regulatory knowledge is a “key knowledge deficit” among academics involved in
commercially focused medical device projects. The European Commission has also cited a
“lack of specific relevant know-how in regulatory science” as a key cause of issues with
translation of scientific research (European Commission, 2020). It is with this in mind that an
EU wide initiative known as STARS (Strengthening Training of Academia in Regulatory Science)
2
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was launched in 2019, with a mandate to increase the awareness of academics to the
regulatory environment (Starokozhko et al., 2020). The former European Medicines Agency
Executive Director Guido Rasi states that “Interaction with EU regulators and a better
understanding of the regulatory environment can help academia translate their discoveries
into patient-focused medicines” (Moulon, 2016). It is believed that early engagement with,
and consideration of, the regulatory requirements associated commercialisation of scientific
research can increase the likelihood of success of commercially focused academic projects
(Starokozhko et al., 2020).

It is interesting to note that funding calls by agencies including the European Commsission’s
Horizon 2020, Enterprise Ireland and the Innovation Medicines Initiative, recognise that
successful applications will be required to consider regulatory issues as part of
commercialisation strategies. For example Enterprise Ireland’s Commercialisation Fund
applications require that “regulatory, reimbursement and other adoption barriers (are)
explored and thought through”, indicating that failure to consider regulatory requirements of
commercially focused projects can lead to unsuccessful funding applications (McShane,
2019). It becomes clear that engaging with the regulatory aspects of commercial projects is
in the interest of the researcher, both from a funding perspective, and if they aspire to see
their innovative discoveries reach the patient bedside.
With increasing focus in universities on the commercialisation of research in recent years,
researchers must now embrace the commercialisation requirements associated with bringing
their novel therapeutics from the laboratory bench to the market, including the regulatory
requirements (Mehta, 2004; van Dongen et al., 2013; Sanami et al., 2017). With this in mind,
and with the backdrop of the EU STARS initiative, this paper aims to gauge the awareness and
knowledge of early stage researchers, academics, and Principal Investigators of the regulatory
requirements associated with commercialisation of academic research. It is hypothesized that
by enhancing their understanding and knowledge of the regulatory requirements, and
encouraging early engagement with the regulatory aspects of commercially focused projects,
speed to market could be increased, while simultaneously decreasing technology transfer
issues that can arise as projects move from academia to industry.

3
Published by ARROW@TU Dublin, 2020

3

Level 3, Vol. 15, Iss. 2 [2020], Art. 7
Level3

Issue 17, December 2020

Technological University Dublin

In addition, this research will aim to determine if there is support for a regulatory pathway
tool to help guide commercially-focused academic projects. The proposed tool would be
similar to, and complement the widely utilised Technology Readiness Level (TRL) tool.
Developed by NASA in the 1970’s, the TRL tool categorises and defines, on a nine-point scale,
the level of maturity or “readiness” of technologies in various stages of development. The TRL
tool allows for effective communication and clear demonstration of the development status
of different technologies (Héder, 2017).
Such is the usefulness of the TRL tool that it was embraced by numerous other organisations
including the US Department of Defence and the European Space Agency. It has since been
adopted as an innovation policy tool in the European Union. In 2014, TRLs were incorporated
into the EU Commission Work Programmes for projects seeking funding as part of the Horizon
2020 programme for Research and Innovation (Héder, 2017). The European Commission
definition of TRLs are summarised in Figure 1. (European Commission, 2014):
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Figure 1: EU Commission TRL definitions

Given the usefulness of the TRL tool in the determination of maturity and readiness of
technologies, this paper seeks to establish if there would be an appetite for a companion
Regulatory Readiness Level (RRL) tool, which is currently under development by a member of
the Pharmaceutical Regulatory Science Team in TU Dublin (www.PRST.ie), for use by
researchers and academics in university settings. The proposed RRL tool would have nine
levels, with each of the nine RRLs corresponding to the associated TRL. The RRL will provide
granular detail at these nine levels as to what is required from a regulatory perspective to
progress from a corresponding TRL to the next. . Where the TRL tool determines maturity of
the technology at each readiness level, the RRL tool would determine the readiness of said
technology with respect to the associated regulatory requirements. A detailed description of
the RRL is available in a separate article in this Journal (McGowran, 2020)
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It is anticipated that the RRL tool would act as a guide for academics for what is required from
a regulatory perspective at each readiness level, allowing them to align with the regulatory
requirements at the associated readiness level. It would also act as a way to measure the
preparedness of their technology from a regulatory perspective. (McGowran, 2020).

2. Aims and objectives of this paper
•

To establish the level of understanding and awareness of the regulatory environment
amongst Early Stage Researchers, Academics, and Principal Investigators.

•

To investigate if there is support for a Regulatory Readiness Level tool to help guide
commercially focused projects.

3. Methodology
Interviews with Subject Matter Experts (SMEs) and a survey of early stage researchers,
academics, and Principal Investigators were carried out to meet the aims and objectives of
this paper.
3.1
Interviews with SMEs:
A total of six semi-structured interviews were carried out with SMEs from a number of Higher
Education Institutions in Ireland in an effort to gain an insight into the perceived
understanding and awareness of early stage researchers and academics of the regulatory
requirements associated with commercialisation of pharmaceutical products and medical
devices. The perspective of these six SMEs, namely Technology Transfer and
commercialisation experts in a number of Irish Universities, regulatory consultants, and
researchers with experience in commercialising scientific research were gathered during the
course of the interviews.
3.2
Survey of Early Stage Researchers, Academics, and Principal Investigators:
It was determined that a survey would be the most appropriate method to employ to gather
the opinions of multiple early stage researchers, academics, and Principal Investigators
involved in commercially focused projects. The survey was distributed online to researchers
active in developing pharmaceuticals, biopharmaceuticals and medical devices in Ireland.
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4. Research Outputs
4.1
Interviews with SMEs:
There were a number of common themes that were identified in the interviews carried out
with SMEs. These included the impact that a lack of understanding and training of researchers
on the regulatory requirements has on commercially focused projects; lack of foresight of
researchers; the link between prior experience of researchers with regulatory requirements
and confidence to engage in the regulatory process; failure of a project is not solely linked to
a lack of regulatory readiness; lack of resources available to assist researchers with regulatory
considerations; benefits to be gained as a result of early engagement with regulatory
requirements; perceived usefulness of the proposed RRL tool; requirement for education of
researchers in regulatory requirements and importance of engaging with same.
4.2
Survey of Early Stage researchers, Academics, and Principal Investigators:
A total of 19 responses were gathered to the survey issued to early stage researchers,
academics, and Principal Investigators, with the breakdown of respondents as follows: Eight
Principal Investigators, six early stage researchers, three academics, and two respondents
selected the “other” category, identifying themselves as a project manager and a grant writer.

Initial questions aimed to establish if respondents believe it is important for them to give
consideration to the regulatory requirements associated with commercialisation of their
scientific research, and if respondents have any previous experience engaging with the
regulatory pathway associated with commercialisation of scientific research. All respondents
agreed that it is important for them to consider the regulatory requirements associated with
their research. 74% of respondents (14/19) indicated that they had some exposure to the
regulatory pathway associated with bringing scientific research to the market.

When asked whether there was any focus on regulatory science aspects of commercialisation
of a product provided during training of researchers and academics involved in commercially
focused projects, 58% (11/19) responded that there was a focus on regulatory science
provided during their training.

7
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Respondents were asked how confident they would feel to engage with the regulatory
process and regulatory authorities in order to prepare their drug candidate/medical device
for commercialisation. No respondents reported feeling extremely confident to engage in the
regulatory process. Responses ranged from “not at all confident” (10%) to “Very confident”
(21%). Approximately the same number of respondents reported feeling “not so confident”
(32%) and “somewhat confident” (37%) to engage with the regulatory requirements
associated with commercialisation of their research.
How confident would you be to engage with the regulatory
process/regulatory authorities in order to prepare your drug
candidate/medical device for commercialisation?

Number of respondents

8
7
6
5
4
3

7

6

2
1

4
2

0

0
Not at all
confident

Not so confident

Somewhat
Very confident
confident
Degree of confidence

Extremely
confident

Figure 2: Confidence of respondents to engage with regulatory process

Barriers preventing their engagement with the regulatory requirements associated with
commercialisation of their research were identified as follows: Complexity of requirements,
lack of knowledge, difficulty in understanding requirements, time constraints, lack of focus of
researchers on regulatory requirements-sole focus on scientific research, lack of
infrastructure in universities to support researchers with regulatory requirements, lack of
funding, high costs associated with contacting out regulatory considerations to experts.

Respondents recognised that there are benefits to early consideration of the regulatory
requirements by researchers and these included: Less waste (time, money, animals etc.),
bring greater focus and clarity to the project, avoidance of rework and revisions, higher
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chance of successful translation of research to the market, encourage researchers to look at
the “bigger picture” and the potential patient impact of their research.

A Likert scale was presented to respondents to gauge the degree to which they agree with
the following statement, “Early consideration of, and engagement with, the regulatory
requirements associated with commercialisation of my research will make the project more
attractive to investors and reduce the time to commercialisation.”(Joshi et al., 2015) No
respondents disagreed with the statement. 1 respondent was neutral, selecting “neither
agree nor disagree”, with the remaining 18 respondents agreeing with the statement to
varying degrees. 37% (7/19) agreed with the statement, while 58% (11/19) strongly agreed.
To what degree do you agree with the following statement - "Early
consideration of, and engagment with, the regulatory requirements
associated with commercialisation of my research will make the
project more attractive to investors and reduce time to comm

Number of respondents

12
10
8
6

11

4

7

2
0

0

0

Strongly disagree

Disagree

1

Neither Agree nor
Agree
Strongly agree
disagree
Degree to which respondents agreed with statement

Figure 3: Degree to which respondents agree that early consideration of regulatory requirements
will make projects more attractive to investors and reduce time to commercialisation

Additionally the following comment was provided - “ A better understanding of the regulatory
environment would help academia/early stage researchers translate their discoveries into
patient focused medicine”, and respondents were once again asked to what degree they
agreed with the statement. All respondents agreed with the statement, with 42% (8/19)
stating they agree, and the remaining 58% (11/19) stating they strongly agree.
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To what degree do you agree with the following statement - "A better
understanding of the regulatory environment would help
academia/early stage researchers translate their discoveries into
patient focused medicine."
Number of respondents

12
10
8

6

11

4

8

2

0

0

Strongly disagree

Disagree

0

0

Neither agree nor
Agree
Strongly agree
disagree
Degree to which respondents agreed with statement

Figure 4: Degree to which respondents agree that having a better understanding of the regulatory
requirements would help them to translate their discoveries into patient focused medicines

Finally, the concept of the RRL tool was introduced and respondents were asked how useful
they would consider such a tool to be to them. All agreed, to some degree, that this tool
would be useful. Equal numbers believed that such a tool would be very useful or extremely
useful (8/19 in both incidences). 16% (3/19) believed the tool would be somewhat useful.
How useful would you consider an RRL tool to be for early stage
researchers?

Number of respondents

9
8
7

6
5
4

8

8

3
2
1
0

3
0

0

Not at all useful

Not so useful Somewhat useful
Very useful
Perceived level of usefulness of RRL tool

Extremely useful

Figure 5: Perceived usefulness of the proposed RRL tool
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5. Discussion
5.1
Impact of the lack of understanding and training of researchers on the regulatory
requirements:
Interviewees agreed that generally, academics and researchers do not have the requisite
training, knowledge, or experience to effectively engage in the regulatory pathway associated
with commercialisation of their scientific research. It was noted that the researchers have
little exposure to the regulatory pathway and often rely on the expertise of external
regulatory consultants to address the regulatory requirements and the associated nuances of
the regulatory pathway. Requirement for external assistance also has additional
repercussions for commercially focused projects; failure to consider regulatory requirements
until such time as consultants are brought into the project results in lost time and the
requirement for remediation work to be carried out to bring the project to the correct point
with respect to the regulatory requirements. As a result, progress of projects is slowed when
consideration is not given to the regulatory requirements. The cost associated with bringing
regulatory experts into a project is also noted to be high.
5.2
Lack of foresight of researchers:
With some early academic discoveries, there may have been no commercial intent at the
outset. Researchers will not recognise the commercialisable nature of their findings until they
are at the “Proof of Concept” stage i.e. at TRL 3. Researchers will often only then begin to
build a commercialisation roadmap and seek funding once they confirm that they have proof
of concept. Therefore, regulatory requirements are only considered post this stage. This can
lead to the requirement for remediation work to bring projects to the correct point with
respect to the previously unconsidered regulatory requirements.
5.3
Link between prior experience of researchers with regulatory requirements and
confidence to engage in the regulatory process:
They acknowledged that for those with no previous experience, engaging with the regulatory
aspects of a project can be very daunting. SMEs report that researchers are fearful of the
regulations and regulators, and their lack the basic knowledge pertaining to the regulations
impedes them from effectively engaging with the process. However, if commercialisation of
the technology is the ultimate goal, it is noted that researchers must become intimately
familiar with the regulations, as this will determine if their technology is commercially viable
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or not. If researchers cannot meet legislative standards, the product that arises from their
research will not become a commercially viable product. If researchers want to commercialise
their research, they should not be afraid of the legislation, but rather should be embracing it.
5.4
Failure of a project is not solely linked to the lack of regulatory readiness:
All interviewees were asked if they had been involved in a project that had failed as a result
of a lack of consideration given to regulatory requirements or lack of “regulatory readiness”.
All respondents concluded that it is not regulatory readiness alone that leads to failure of
projects, but it can be a contributing factor. Lack of consideration of the regulatory
requirements associated with commercialisation of scientific research can significantly delay
a project, preventing advancement until regulatory requirements are remediated, and can
also contribute to unsuccessful funding applications. It can also make projects less attractive
to potential investors.
5.5
Lack of resources available to assist with regulatory considerations:
The SMEs interviewed highlighted that there are good supports in place to assist researchers
with various aspects of commercialisation of their research, for example management of
Intellectual Property. However, they note that there are no specific supports in place in
universities to aid researchers with the regulatory aspects of such projects.

A number of the SMEs explain that while funding is available to progress research on the path
to commercialisation, the amount is finite and often does not extend to cover the costs
associated with the regulatory pathway. In one SME’s opinion, funding “never goes far
enough, which means you don’t have the resources to bring in the required expertise.” It is
interesting to consider the usefulness of the RRL tool in light of this finding, as if there are
insufficient funds available to engage regulatory consultants, having a tool to guide
researchers through the regulatory pathway, would be very beneficial, both in terms of time
and cost savings.
5.6
Benefits of early engagement with regulatory requirements by researchers:
The researcher was eager to understand if the SMEs believed that increasing the awareness
of early stage researchers to the regulatory requirements would increase the speed of
commercialisation and decrease the number of drugs lost to the Valley of Death.

12
https://arrow.tudublin.ie/level3/vol15/iss2/7
DOI: https://doi.org/10.21427/jp6q-7t23

12

Harris and O'Reilly: from idea to therapeutic
Level3

Issue 17, December 2020

Technological University Dublin

Interviewees all agreed that the speed of commercialisation could be increased and enhanced
if researchers had a greater awareness and understanding of the regulatory requirements
applicable to their stage of research. All SMEs agreed that research projects that give
consideration to regulatory requirements and have a plan in place to address same early in
the timeline of the project, will become instantly more attractive to investors. Building in the
regulatory pathway and demonstrating to investors that not alone has the project
demonstrated proof of concept and has a commercialisation roadmap in place, but has also
benchmarked the project against the regulatory standards will impress potential investors.

With respect to decreasing the number of drugs lost to the Valley of Death, interviewees all
concluded that early stage therapeutic projects tend to be lost as a result of issues relating to
funding, more so than as a direct result of issues relating to the regulatory readiness of the
research. If financial support of the project is limited, it is unlikely that there are any
supplemental funds available to spend on regulatory consultants. If researchers had a greater
understanding of the requirements and did not require external assistance, which comes at a
high price, this would be beneficial to the project as a whole.
5.7
Perceived usefulness of the proposed RRL tool:
When asked if they believed an RRL tool would be useful, SMEs were all in agreement that it
would be a very useful tool to guide early stage researchers along the regulatory pathway.

Having a recognised tool that lays out the pathway and requirements to coincide with their
research timelines would be very useful for researchers. Such a tool would provide a roadmap
to researchers who have little to no understanding of the requirements and guide them
through the process. It was noted that the introduction of such a tool would be timely, with
interest in academic and university settings in commercialising research increasing in recent
years. SMEs were keen to stress that such a tool must be simple to use and not dissuade
researchers from engaging with the regulatory aspects of a project.

One SME, a researcher with experience in commercialisation, raised an interesting point
regarding the usefulness of the RRL tool for early stage researchers that links to the issue that
arises as a result of a lack of foresight of researchers. If the researcher is working towards
13
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commercialisation from the outset, he agrees that a companion regulatory framework tool
would be massively beneficial. However, if the researcher in engaging in “blue sky research”
and does not recognise the commercial potential of their discoveries for some time, it is less
likely that they will engage with an RRL tool at this early stage. If they are solely focused on
their research and subsequently provided with reams of documents pertaining to regulatory
requirements, they will feel this is not relevant to them or their research and will not engage.
Perhaps if the seed of commercialisation potential of scientific research was sown from an
early stage, and the benefits of considering the regulatory requirements that would be
applicable at say TRL 1,2, and 3 were highlighted, early stage researchers may be more likely
to engage.
One SME noted that researchers and academics are very familiar with the TRL concept and
associated language and thus, this would help researchers understand the standing of their
technology with respect to the regulatory requirements. The proposed alignment of the RRL
tool with the TRL concept was well received.
5.8
Requirement for education of researchers with respect to regulatory requirements:
It was noted by interviewees that for early stage researchers and academics, a degree of “buyin” will need to be fostered in order to impress upon researchers the importance of, and
benefits of, their early engagement with the regulatory aspects of their project. As this is not
something that is currently within their remit, without education pertaining to its importance,
there may be some resistance. Researchers must be educated to understand that making
their asset more commercialisable (through, for example, considering regulatory
requirements at an early stage) ultimately increases the value of their opportunity.
5.9
Survey of early stage researchers, academics, and Principal Investigators:
With 100% of respondents agreeing that it is important for them to give consideration to the
regulatory requirements associated with their scientific research, it is clear that awareness of
said requirements among this cohort is high. The majority of respondents also recognised the
benefits that engagement with the regulatory requirements will confer on a project. What is
interesting to note is that this awareness is not matched with a high level of confidence to
engage with the regulatory aspects of their projects. Equally, having previous experience
navigating the regulatory pathway associated with commercialisation of research did not
14
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result in a significant increase in confidence of researchers to engage; of the 14 respondents
who reported having previous experience engaging with the regulatory requirements, only 4
reported feeling very confident to engage with the regulatory process in order to prepare
their scientific research for commercialisation. The remaining 10 respondents reported that
they would feel “not so confident” (3/14) and “somewhat confident” (7/14). The high level of
awareness does not result in an increased likelihood or confidence to engage with the
regulatory aspects of a project.
The barriers to engagement with regulatory aspects of commercially focused projects noted
by researchers were aligned with those identified by the SMEs. The most frequently cited
barrier was lack of knowledge and understanding of the complex and difficult to interpret
regulations. This is followed closely by lack of funding and high costs associated with bringing
regulatory consultants into the project. The proposed RRL tool has the potential to help
researchers circumnavigate these barriers by providing a clear pathway, detailing the exact
regulatory requirements as the project progresses.

Again, the benefits of early engagement with the regulatory requirements identified by
reserachers coincided with those expressed by SMEs. Efficiency, avoidance of revision and
rework, optimisation and refinement of the pathway to commercialisation, and time and cost
saving in the long run were the most frequently cited benefits.

Recognition that early familiarity with the regulatory requirements will make projects more
attractive to investors and will reduce time to commercialisation was high among
researchers, corroborating the sentiments of SMEs. Researchers also generally agreed that
having a better understanding of the regulatory requirements will help them to translate their
discoveries into patient focused medicine, echoing the sentiment of SMEs, and former EMA
Executive Director Guido Rasi. This again confirms that the awareness of the importance of
the regulatory requirements among researchers is high. While they may be reluctant to
engage, it is clear that they have a good understanding and awareness of the potential
benefits that could be gained should they they choose to actively engage with regulatory
aspects of their scientific research.
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What can be deduced from the above is that awareness of the regulatory requirements is not
the key issue; knowledge and confidence to engage is. The positive reaction to the RRL tool
also further highlights that researchers would likely engage in the process themselves if there
was a support tool available to guide and direct them.
5.10 Comparison of Opinions of SMEs and Researchers elucidated through interviews
and surveys respectively
When comparing responses from both SMEs and researchers, it was interesting to note that
their opinions were not completely in alignment. Both cohorts identified similar barriers and
benefits to early engagement of researchers with regulatory requirements, and also agreed
that the proposed RRL tool would be beneficial for researchers. However, SMEs felt that
researchers had little awareness of the regulatory requirements, do not recognise their
importance, and have little to no formal training with respect to these requirements. This was
not in line with the findings of the survey, where 100% of respondents agreed that it is
important for researchers to give consideration to the regulatory requirements of their
research, and 58% reported receiving training relating to regulatory science. SMEs believe
significant education of researchers will be required in order to impress the importance of
the regulatory aspects of their research upon them, however the results of the surveys of
researchers indicate that their awareness of the importance of this aspect of their research is
already high. The differences and similarities in the opinions of both parties are presented in
table 1.
Table 1: Comparison of opinions of SMEs and researchers elucidated through interviews and
surveys respectively
Awareness of researchers of
regulatory requirements
Importance of regulations to
researchers
Training of researchers with
respect to regulatory science
Perceived barriers to
engagement of researchers
with regulatory aspects of
their research

•
•
•
•
•

Opinion of SMEs

Opinion of Researchers

Low

High

Low

High

None

Some -58% of respondents
report receiving training
In line with SMEs opinions

Lack of knowledge
Lack of funding
Lack of infrastructure to
support regulatory
aspects of projects
Complexity of
requirements
Not experts in this area
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•
•
Perceived benefits to
engagement of researchers
with regulatory aspects of
their research

•
•
•
•
•

Usefulness of RRL tool

Not focused on
commercial nature of
discoveries
Fear of regulations and
regulatory authorities
Increased
attractiveness of
project to investors
Time saving in the long
run
Clearer pathway to
market
Higher chance of
successful translation
to the market
Increased speed of
project to
commercialisation
Very useful

Technological University Dublin

In line with SMEs opinions

Very useful

6. Future Work in this area
SMEs and researchers both cited a lack of knowledge of the regulatory environment as a
barrier to the engagement of researchers with this aspect of drug development. Research
into the current training pertaining to regulatory science, both at undergraduate and
postgraduate level, could be investigated to determine if this identified gap is as significant
as it appears in the findings of this research. It would be interesting to understand if
incorporation of structured regulatory science training into undergraduate and postgraduate
Life Science degree programs would increase the confidence of future researchers to engage
with the regulations, and bridge the knowledge gap that is evident for current researchers.

The research for this paper was limited to an Irish context and it would be valuable to
establish if this was mirrored in other countries.

Investigations into the differing opinions of SMEs and researchers could be examined in more
detail to understand the reason for the apparent divergence in the opinions of both parties.
For example, it would be interesting to determine why the SMEs interviewed believe that
researchers have little awareness of regulatory requirements and their importance, despite
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all survey respondents reporting high awareness and understanding of the importance of the
regulatory requirements associated with their scientific research.

Most importantly, work on the development, validation, and implementation of the RRL tool
in academic settings, followed by investigations into the real world application and usefulness
of the RRL tool needs to be progressed.

7. Conclusions
Through interviews with SMEs and a survey of early stage researchers, academics, and
Principal Investigators, it is clear that while all stakeholders agree that it is important for
researchers to give consideration to the regulatory requirements associated with
commercialisation of scientific research, at present, researchers do not have the knowledge
or expertise to fully and confidently engage in the process. The high level of awareness of
researchers of the importance of early consideration of the regulatory aspects of their work
and the acknowledgement and understanding of the benefits that will be conferred on a
project through their engagement with same was encouraging.

A number of benefits to early consideration of, and engagement with, the regulatory
requirements by researchers were confirmed throughout the course of this research. These
include increased speed of a project to commercialisation, increased attractiveness of a
project to potential investors, a clearer path to the market for basic scientific research, and
reduced need for remediation with respect to regulatory requirements of commercially viable
projects in later stages of development that may not have given early consideration to same.

The proposed RRL tool was well received by both SMEs and survey respondents, indicating
that there would be support among stakeholders for a tool to guide researchers through the
requirements of each stage of the regulatory pathway, thereby increasing their confidence to
engage with the regulatory requirements associated with their research and discoveries. The
barriers to engagement with regulatory aspects of commercially focused projects, namely
complexity of the requirements and knowledge deficits of researchers in this regard, could
potentially be overcome and ameliorated with the introduction and utilisation of the
proposed RRL tool.
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To conclude, the words of one of the SMEs interviewed for this research summarises the
premise of this paper well: “An excellent academic who has a better understanding of the
regulatory pathway, the timelines, and what is required, can only be a good thing.”
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